Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $51.40

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average rating of “Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $51.40.

Several analysts recently commented on DYN shares. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Morgan Stanley raised their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Guggenheim lifted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.

Insider Transactions at Dyne Therapeutics

In other news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares in the company, valued at approximately $4,849,956.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,975 shares of company stock worth $5,693,789 over the last ninety days. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of DYN. Wellington Management Group LLP grew its holdings in Dyne Therapeutics by 25.5% in the fourth quarter. Wellington Management Group LLP now owns 145,474 shares of the company’s stock valued at $1,935,000 after purchasing an additional 29,539 shares during the period. Principal Financial Group Inc. grew its stake in Dyne Therapeutics by 5.9% during the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after buying an additional 857 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Dyne Therapeutics by 24.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock worth $812,000 after buying an additional 5,696 shares during the period. Capstone Investment Advisors LLC purchased a new stake in Dyne Therapeutics during the first quarter worth approximately $575,000. Finally, Jennison Associates LLC grew its stake in Dyne Therapeutics by 495.2% during the first quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock worth $34,282,000 after buying an additional 1,004,680 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $33.39 on Wednesday. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $47.45. The stock has a fifty day moving average price of $37.36 and a two-hundred day moving average price of $34.62. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -8.46 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts predict that Dyne Therapeutics will post -2.96 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.